Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | US

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
PRECISION BIOSCIENCES INC A clinical-stage company using ARCUS gene editing to treat cancer and rare genetic diseases.	United States of America	DTIL
Precision Biosensor Inc. Develops sensitive point-of-care biomarker diagnostics for human and animal health.	South Korea	335810
Prelude Therapeutics Inc Clinical-stage oncology company developing novel protein degraders and ADCs for cancer.	United States of America	PRLD
Prestige Biologics Co., Ltd. A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.	South Korea	334970
Prestige BioPharma Limited Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.	Singapore	950210
Prestige Consumer Healthcare Inc. Develops and markets leading over-the-counter brands for personal healthcare and wellness.	United States of America	PBH
Processa Pharmaceuticals, Inc. Develops next-gen chemo and therapies for chronic and life-threatening diseases.	United States of America	PCSA
ProGen, Co,, LTD. Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.	South Korea	296160
PROKIDNEY CORP. Develops cellular therapies to preserve kidney function for patients with advanced Chronic Kidney Disease.	United States of America	PROK
ProMIS Neurosciences Inc. Developing selective antibody therapies targeting toxic proteins in neurodegenerative diseases.	United States of America	PMN